(+/-)-2-(1-pyrrolidinyl)butanol | 135711-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (+/-)-2-(1-pyrrolidinyl)butanol
• 英文别名: 2-(1-Pyrrolidinyl)butanol；2-pyrrolidin-1-ylbutan-1-ol
• CAS: 135711-17-0
• 化学式: C₈H₁₇NO
• 分子量: 143.229
• InChiKey: MPOXJNRKFHZSFT-UHFFFAOYSA-N

物化性质

• 沸点：
  219.1±13.0 °C(Predicted)
• 密度：
  0.981±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (+/-)-2-(1-pyrrolidinyl)butanol 在 双氧水 作用下， 生成 2-(1-Oxy-pyrrolidin-1-yl)-butan-1-ol
  参考文献：
  名称：

  碳α转化为仲胺氮的新烷基化方法

  摘要：

  提出了一种将碳α烷基化为仲胺1a，c-g的氮的方法，该方法基于从β-羟基叔胺N-氧化物2高效合成新的恶唑烷3的方法。

  DOI：

  10.1016/0040-4039(91)80353-8
• 作为产物：
  描述：

  2-Pyrrolidin-1-yl-butyric acid ethyl ester 在 lithium aluminium tetrahydride 作用下， 生成 (+/-)-2-(1-pyrrolidinyl)butanol
  参考文献：
  名称：

  Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 3. Enhancing activity by imposing conformational restriction in the C-4″ side chain1

  摘要：

  The preparation and biological evaluation of a series of benzo[b]thiophene diamine thrombin inhibitors possessing conformationally restricted C-4" linkers are reported. Compared to the parent compounds 1a/b, the unsaturated derivatives 3a/b exhibited a modest twofold increase in thrombin inhibitory activity, while the more lipophilic carbocyclic ring containing analogs 4a/b, affected an eightfold enhancement in potency. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00746-x

文献信息

• Substituted aryl or heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
  申请人：Santhera Pharmaceuticals (Schweiz) AG

  公开号：EP2020405A1

  公开（公告）日：2009-02-04

  The present invention relates to substituted aryl or heteroarylpiperidine derivatives of structure (I) as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及结构式(I)的取代芳基或杂芳基哌啶衍生物，作为黑色素皮质素-4受体调节剂。根据结构和立体化学，本发明的化合物可以是人类黑色素皮质素-4受体(MC-4R)的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖、糖尿病和性功能障碍等疾病，而拮抗剂可用于治疗癌症恶病质、肌肉消耗、厌食症、焦虑和抑郁等疾病。一般来说，所有涉及MC-4R调节的疾病和疾病都可以用本发明的化合物进行治疗。
• [EN] ANTITHROMBOTIC DIAMINES<br/>[FR] DIAMINES ANTITHROMBOTIQUES
  申请人：ELI LILLY AND COMPANY

  公开号：WO1997025033A1

  公开（公告）日：1997-07-17

  (EN) This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula (I) as defined herein. It also provides novel compounds of formula (I), processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula (I).(FR) La présente invention concerne l'utilisation, comme inhibiteurs de thrombine, inhibiteurs de coagulation et agents destinés aux désordres de la thromboembolie, de diamines de formule I telle qu'elle est définie dans la description. L'invention concerne aussi des composés nouveaux de formule I, des procédés et des produits intermédiaires pour leur préparation, et des formulations pharmaceutiques comprenant les composés nouveaux de formule I.

  该应用涉及使用公式（I）所定义的二胺作为凝血酶抑制剂、凝血抑制剂和血栓栓塞疾病药物的用途。它还提供了公式（I）的新化合物、其制备过程和中间体，以及包含公式（I）的新药物配方。
• Antithrombotic diamines
  申请人：Eli Lilly and Company

  公开号：US06265575B1

  公开（公告）日：2001-07-24

  This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

  本申请涉及使用式I所定义的二胺作为凝血酶抑制剂、凝血抑制剂和血栓性疾病药物的用途。它还提供了式I的新化合物、其制备的过程和中间体，以及包含式I的新药物制剂。
• Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators
  申请人：Henneböhle Marco

  公开号：US20100249093A1

  公开（公告）日：2010-09-30

  The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators. Depending on the structure and the stereochemistry the compounds of the invention are either selective agonists or selective antagonists of the human melanocortin-4 receptor (MC-4R). The agonists can be used for the treatment of disorders and diseases such as obesity, diabetes and sexual dysfunction, whereas the antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, amyotrophic lateral sclerosis (ALS), anxiety and depression. Generally all diseases and disorders where the regulation of the MC-4R is involved can be treated with the compounds of the invention.

  本发明涉及取代杂环基哌啶衍生物作为黑色素-4受体调节剂。根据化合物的结构和立体化学，本发明的化合物可以是人类黑色素-4受体（MC-4R）的选择性激动剂或选择性拮抗剂。激动剂可用于治疗肥胖症、糖尿病和性功能障碍等疾病和疾病，而拮抗剂可用于治疗癌症消耗症、肌肉萎缩、厌食症、肌萎缩侧索硬化症（ALS）、焦虑和抑郁症等疾病和疾病。通常，涉及MC-4R调节的所有疾病和疾病都可以用本发明的化合物治疗。
• EP0863755A4
  申请人：——

  公开号：EP0863755A4

  公开（公告）日：1999-01-20